Futura Medical (GB:FUM) has released an update.
Futura Medical PLC reports a soaring 300% revenue growth to £7.0 million and a maiden profit of £1.0 million for the first half of 2024, outperforming market expectations. The success was driven by strong product sales and a commercial milestone from the US launch of Eroxon®, their innovative erectile dysfunction treatment. With Eroxon® now available for pre-order in the US and further international expansion on the horizon, Futura’s financial health looks robust as they anticipate further milestone payments and growth.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.
